Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43216   clinical trials with a EudraCT protocol, of which   7153   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-003990-23
    Sponsor's Protocol Code Number:BP42698
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-05-20
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-003990-23
    A.3Full title of the trial
    A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWING STEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS
    STUDIO DI FASE 2, IN DOPPIO CIECO, RANDOMIZZATO, A GRUPPI PARALLELI TESO A VALUTARE L'EFFETTO DI RO7049665 SUL TEMPO ALLA RECIDIVA DOPO RIDUZIONE DEGLI STEROIDI IN PAZIENTI CON EPATITE AUTOIMMUNE
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune Hepatitis
    Studio di fase 2, in doppio cieco, a gruppi paralleli teso a valutare l'effetto di RO7049665 in pazienti con epatite autoimmune
    A.3.2Name or abbreviated title of the trial where available
    -
    -
    A.4.1Sponsor's protocol code numberBP42698
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. HOFFMANN - LA ROCHE LTD.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF. Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number000000
    B.5.5Fax number0000000
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIgG IL2/RO7049665
    D.3.2Product code [RO7049665]
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2056881-92-4
    D.3.9.2Current sponsor codeRO7049665
    D.3.9.3Other descriptive nameRO7049665/IgG-IL2/ IgG-IL2ND2
    D.3.9.4EV Substance CodeSUB187103
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection/infusion
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Autoimmune Hepatitis (AIH)
    Epatite Autoimmune (AIH)
    E.1.1.1Medical condition in easily understood language
    AIH is a chronic disease in which your body's immune system attacks the liver and causes inflammation and liver damage
    L'AIH è una malattia cronica in cui il sistema immunitario del tuo corpo attacca il fegato e provoca infiammazione e danni al fegato
    E.1.1.2Therapeutic area Diseases [C] - Hormonal diseases [C19]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10003827
    E.1.2Term Autoimmune hepatitis
    E.1.2System Organ Class 10019805 - Hepatobiliary disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    AIH is a chronic disease in which your body's immune system attacks the liver and causes inflammation and liver damage
    • Valutare l'effetto di RO7049665 sul tempo alla recidiva dopo riduzione forzata dei CCS, misurata come il rapporto di rischio tra 7,5 mg di RO7049665 e placebo.
    E.2.2Secondary objectives of the trial
    •To assess changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and IgG over time and by dose
    •To evaluate the effect of RO7049665 on time to relapse following forced CCS tapering as measured by the hazard ratio between 3.5 mg RO7049665 and placebo
    •To evaluate the safety and tolerability of RO7049665 in participants with AIH
    • Valutare i cambiamenti nei livelli di alanina aminotransferasi (ALT), aspartato aminotransferasi (AST) e immunoglobulina G (IgG) nel tempo e in base alla dose
    • Valutare l'effetto di RO7049665 sul tempo alla recidiva dopo riduzione forzata dei CCS, misurata come il rapporto di rischio tra 3,5 mg di RO7049665 e placebo.
    • Valutare la sicurezza e la tollerabilità di RO7049665 in partecipanti con AIH.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Age
    •Age between 18 to 75 years
    Type of Participants and Disease Characteristics
    •Patients with a definite diagnosis of AIH (type 1, 2 and 3) as per
    simplified or revised original diagnostic criteria
    •Patients who have been in biochemical remission for > 2 years prior to
    randomization
    •Patients who have been on stable treatment for at least 6 months prior
    to randomization
    •No signs of liver inflammation on a liver biopsy taken no more than 12
    months prior to randomization.
    •Patients with AIH who have previously not attempted to taper CCS to 0
    mg/day
    Weight
    •Body mass index within the range of 18-35 kg/m2 (inclusive)
    Sex and Contraception/Barrier Requirements
    •Women of childbearing potential, who: agree to remain abstinent or
    use at least one acceptable contraceptive methods during the treatment
    period and for at least 28 days after the final dose of study drug
    Età
    • Età compresa tra 18 e 75 anni

    Tipo di partecipanti e caratteristiche della malattia
    • Pazienti con una diagnosi definita di AIH (tipo 1, 2 e 3) secondo i criteri diagnostici originali semplificati
    • Pazienti in remissione biochimica da ¿ 2 anni prima della randomizzazione.
    • Pazienti in trattamento stabile da almeno 6 mesi prima della randomizzazione.
    • Nessun segno di infiammazione epatica alla biopsia epatica eseguita nei 12 mesi che precedono la randomizzazione.
    • Pazienti con AIH che in precedenza non hanno tentato una riduzione dei CCS a 0 mg/die.
    Peso
    • Indice di massa corporea compreso nell'intervallo 18 35 kg/m2 (compresi).
    Requisiti relativi ad attività sessuale e contraccezione/barriera
    • Donne in età fertile che: accetta di astenersi dai rapporti eterosessuali o di usare almeno un metodo contraccettivo accettabile durante il periodo di trattamento e per almeno 28 giorni dopo la dose finale del farmaco in studio.
    E.4Principal exclusion criteria
    Medical Conditions
    •Patients with cirrhosis (F4 fibrosis by Fibroscan®) with significant impairment of liver function (Child Pugh category B or C)
    •Any other autoimmune disease requiring immunomodulating treatment
    •History of infection with hepatitis B, human immunodeficiency virus, active hepatitis C virus (HCV) infection, detection of replicating CMV or
    Epstein-Barr virus (EBV)
    •Active infections requiring systemic therapy with antibiotic, antiviral, or antifungal treatment or febrile illness within 7 days before Day-1
    •History of primary or acquired immunodeficiency
    •Female patients: Pregnant or lactating
    •Symptomatic herpes zoster within 3 months prior to screening
    •History of active or latent tuberculosis or a positive Quantiferon Gold test
    •History of clinically significant severe drug allergies, multiple drug allergies, allergy to any constituent of the product, or intolerance to topical steroids
    •Lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years and in situ carcinoma of the cervix that was completely removed surgically. Breast cancer within the past 10 years
    •Significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
    •Any condition or disease detected during the medical interview/physical examination that would render the patient unsuitable for the study, place the patient at undue risk, or interfere with the ability
    of the patient to complete the study in the opinion of the Investigator
    Prior/Concomitant Therapy
    •CCSs of < 5 mg/day, or < 2.5 mg CCSs plus immune suppressant, or <
    3 mg/day budesonide with or without immune suppressant
    •CCSs > 20 mg/day or > 9 mg/day budesonide
    •NSI daily dose higher than recommended standard of care therapy
    •T or B cell-depleting therapy within the last 12 months or T- or B-cell
    number below normal due to depleting therapy
    Prior/Concurrent Clinical Study Experience
    •Leukocyte apheresis within 12 weeks of screening.
    •Donation of blood or blood products in excess of 500 mL within 3
    months prior to screening.
    •Exposure to any investigational treatment within 6 months prior to Day
    1
    Laboratory Abnormalities
    •Abnormal hematologic, hepatic enzyme or hepatic function, biochemistry values
    Other Exclusions
    •History of regular alcohol consumption within 2 months of screening
    •Any suspicion or history of illicit drug use
    •Patients under judicial supervision, guardianship, or curatorship
    • Pazienti con cirrosi (fibrosi F4 con Fibroscan®) con compromissione significativa della funzionalità epatica (categoria B o C della classificazione Child Pugh).
    • Qualsiasi altra malattia autoimmune (inclusa sindrome da overlap) che richieda un trattamento immunomodulante.
    • Storia di infezione da virus dell'epatite B e/o per anti HBc infezione da virus dell'immunodeficienza umana (HIV; test per gli anticorpi anti-HIV positivo), infezione attiva da virus dell'epatite C (HCV) (RNA di HCV rilevabile), identificazione di CMV o virus di Epstein-Barr replicante.
    • Infezioni attive che richiedano terapia sistemica con antibiotici, antivirali o antifungini o malattia febbrile nei 7 giorni che precedono il giorno ¿1.
    • Anamnesi di immunodeficienza primaria o acquisita.
    • Pazienti femmine: gravidanza o allattamento con latte materno.
    • Herpes zoster sintomatico nei 3 mesi precedenti lo screening.
    • Anamnesi di tubercolosi attiva o latente o un test Quantiferon¿ Gold positivo.
    • Anamnesi di gravi allergie ai farmaci clinicamente significative, allergie a più farmaci, allergia a uno qualsiasi dei componenti del farmaco in studio o intolleranza agli steroidi per uso topico.
    • Linfoma, leucemia o qualsiasi tumore maligno nei precedenti 5 anni, tranne carcinoma a cellule basali o squamose della pelle che è stato resecato e non presenta evidenza di metastasi da 3 anni e carcinoma della cervice in situ che è stato rimosso completamente mediante chirurgia. Carcinoma mammario nei 10 anni precedenti.
    • Comorbilità significativa non controllata, quali patologie cardiache, polmonari, renali, epatiche, endocrine o gastrointestinali.
    • Qualsiasi condizione o patologia rilevata durante l'intervista medica/l'esame obiettivo che potrebbe rendere il paziente non idoneo allo studio, porre il paziente a un rischio superfluo o interferire con la capacità del paziente di completare lo studio secondo il parere dello sperimentatore.
    Terapie precedenti/concomitanti
    • CCS minore 5 mg/die o CCS < 2,5 mg più immunosoppressore o budesonide < 3 mg/die con o senza immunosoppressore.
    • CCS maggiore20 mg/die o budesonide > 9 mg/die.
    • Dose giornaliera di NSI maggiore dello standard di cura raccomandato.
    • Terapia di deplezione dei linfociti T o B (per es., rituximab) negli ultimi 12 mesi o conta dei linfociti T o B inferiore al normale a causa della terapia di deplezione
    Precedente/concomitante esperienza in uno studio clinico
    • Aferesi di linfociti nelle 12 settimane precedenti lo screening.
    • Donazione di sangue o emoderivati superiore a 500 ml nei 3 mesi che precedono lo screening.
    • Esposizione a qualsiasi prodotto sperimentale nei 6 mesi che precedono il giorno 1.
    • Valori ematologici anormali, Valori anormali degli enzimi epatici o della funzionalità epatica, Valori di biochimica anormali:
    Altre esclusioni
    • Storia di consumo regolare di alcool nei 2 mesi che precedono lo screening,
    • Sospetto o storia di consumo di droghe.
    • Pazienti sottoposti a sorveglianza giudiziaria, custodia o tutela.
    E.5 End points
    E.5.1Primary end point(s)
    Time to relapse from randomization
    Tempo alla recidiva dall'inizio della randomizzazione
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint will be assessed when the required number of events has occurred (Approximately 60 months)
    L'endpoint primario sarà valutato quando il numero richiesto di eventi si sono verificatii (Circa 60 mesi)
    E.5.2Secondary end point(s)
    Efficacy
    1.ALT, AST, and IgG (for both ¿, absolute and relative [upper limit of
    normal]) over time
    2.Time to relapse from randomization
    3.Incidence and severity of adverse events
    4.Changes in vital signs, physical examination, ECG parameters, and
    safety laboratory parameters
    5.Anti-drug antibody emergence and neutralizing potential
    Efficacy
    1.ALT, AST, and IgG (for both ¿, absolute and relative [upper limit of
    normal]) over time
    2.Time to relapse from randomization
    3.Incidence and severity of adverse events
    4.Changes in vital signs, physical examination, ECG parameters, and
    safety laboratory parameters
    5.Anti-drug antibody emergence and neutralizing potential
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-5. The secondary endpoints will be assessed when the required number of events has occurred (Approximately 60 months)
    1-5. The secondary endpoints will be assessed when the required number of events has occurred (Approximately 60 months)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA16
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Germany
    Italy
    Korea, Democratic People's Republic of
    Korea, Republic of
    Netherlands
    New Zealand
    Portugal
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 50
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 34
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 56
    F.4.2.2In the whole clinical trial 84
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Return to standard of care
    Ritoranre alla sura standard
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-03-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-03-11
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA